Since Enhertu's successes, the next antibody-drug conjugates (ADC)，Patritumab deruxtecan, emerging from Daiichi Sankyo's pipeline, has been closely watched. Patritumab deruxtecan (HER3-DXd) includes a human anti-HER3 monoclonal antibody covalently bound to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker, which interrupts DNA replication in cancer cells.

Patritumab deruxtecan (HER3-DXd) is active in patients with heavily pretreated HER3-expressing metastatic breast cancer, according to results of a phase 1/2 study presented during the 2022 ASCO Annual Meeting by Ian E. Krop, MD, PhD, with a confirmed objective response rate (ORR) of 30% and a toxicity-related discontinuation rate of 10%. Besides, HER3-DXd have Efficacy in Lung Cancer. In December 2021, the FDA granted a breakthrough therapy designation to Patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non–small cell lung cancer (NSCLC) with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.

Immune Checkpoint Proteins

GMP Grade Cytokines

Multi-pass Tps